Egrifta (Tesamorelin) + GHK-Cu Stack: Complete Protocol

What Are Tesamorelin and GHK-Cu Individually?

Tesamorelin is a synthetic analogue of endogenous growth-hormone-releasing hormone (GHRH). The FDA approved Egrifta in 2010 and the updated Egrifta SV formulation in 2019 specifically for reducing excess visceral adipose tissue in HIV-infected adults with lipodystrophy [1]. GHK-Cu is a tripeptide (glycine-histidine-lysine) complexed with copper(II) that occurs naturally in human plasma, saliva, and urine; plasma concentrations decline from roughly 200 ng/mL at age 20 to under 80 ng/mL after age 60 [2].

Tesamorelin: Mechanism of Action

Tesamorelin binds pituitary GHRH receptors and stimulates pulsatile growth hormone (GH) secretion, which in turn raises insulin-like growth factor-1 (IGF-1). In the key Phase 3 LIPO trials (combined N = 816), subcutaneous tesamorelin 2 mg/day reduced visceral adipose tissue by 15 to 18% versus placebo at 26 weeks (P<0.001) [3]. GH also promotes lipolysis through hormone-sensitive lipase activation, explaining the visceral fat effect [4].

GHK-Cu: Mechanism of Action

GHK-Cu activates over 4,000 human genes according to a 2012 microarray analysis, with the largest clusters in tissue remodeling and anti-inflammatory pathways [5]. The peptide upregulates collagen, elastin, and glycosaminoglycan synthesis, and it modulates TGF-beta signaling. A 2001 study in Wound Repair and Regeneration showed GHK-Cu accelerated wound closure by 33% versus control in excisional rat models [6]. Its anti-inflammatory effects appear partly mediated through NF-kB inhibition [7].

Why Stack Tesamorelin With GHK-Cu?

The rationale centers on complementary, non-overlapping mechanisms. Tesamorelin acts primarily through the GH/IGF-1 axis to reduce visceral fat and support lean mass. GHK-Cu acts through extracellular matrix remodeling and local tissue signaling, independent of the GH axis. Combining agents with different receptor targets reduces the risk of receptor desensitization and may produce additive tissue benefits that neither peptide achieves alone.

GH Axis Meets Tissue Remodeling

Elevated IGF-1 from tesamorelin stimulates fibroblast proliferation [8]. GHK-Cu provides the copper-dependent scaffolding signals that fibroblasts need to deposit organized collagen. A 2015 paper in Archives of Biochemistry and Biophysics demonstrated that GHK-Cu increased collagen synthesis in cultured human fibroblasts by 70% at a concentration of 1 nM [9]. Tesamorelin-driven IGF-1 elevation may prime fibroblasts to respond more strongly to GHK-Cu's collagen signals, though this specific interaction has not been tested in humans.

Body Composition and Skin Quality

Practitioners report that patients using tesamorelin for visceral fat reduction often note concurrent skin laxity as subcutaneous fat redistributes. GHK-Cu's established skin-remodeling activity [10] addresses this cosmetic concern directly. A double-blind trial published in Journal of Cosmetic Dermatology (N = 67) found a GHK-Cu-containing topical formulation improved skin density by 14% and reduced fine lines by 35% versus vehicle after 12 weeks [11]. Subcutaneous GHK-Cu, as used in peptide protocols, is expected to produce stronger systemic concentrations, although direct bioavailability comparisons between topical and subcutaneous routes have not been published.

Cognitive and Neuroprotective Overlap

Tesamorelin has attracted research attention beyond lipodystrophy. A randomized trial in JAMA Neurology (N = 152) found 20 weeks of tesamorelin improved verbal memory scores in older adults with mild cognitive impairment (MCI), with a standardized mean difference of 0.46 versus placebo [12]. GHK-Cu shows independent neuroprotective signals in animal models; a 2018 Frontiers in Aging Neuroscience study found GHK reversed age-related gene expression changes in mouse brain tissue, including upregulation of BDNF-related pathways [13]. Whether the two agents produce additive cognitive effects in humans is unknown.

Complete Stack Protocol

No published clinical protocol exists for this specific combination. The schedule below is synthesized from the FDA-approved tesamorelin prescribing information [1], published GHK-Cu peptide research [6][9], and practitioner-reported frameworks. Treat it as a starting scaffold to be individualized by a prescribing physician.

Tesamorelin Dosing

• Dose: 2 mg subcutaneously once daily (the FDA-approved dose for Egrifta SV)
• Injection site: Abdomen, rotated daily
• Timing: Evening, 60 to 90 minutes after the last meal, to align with natural nocturnal GH pulsatility
• Reconstitution (Egrifta SV): Inject 2.1 mL of supplied diluent into the 2 mg vial; gently swirl, do not shake
• Storage: Refrigerate unreconstituted vials at 2 to 8°C; use reconstituted solution within 24 hours

The FDA prescribing information specifies that tesamorelin should be discontinued if the patient does not show a reduction in visceral fat after 26 weeks of use [1]. Off-label users typically run 12 to 24 week cycles.

GHK-Cu Dosing

GHK-Cu carries no FDA-approved subcutaneous dose. Practitioner-reported protocols most commonly use:

• Dose range: 1 to 3 mg subcutaneously once daily
• Starting dose: 1 mg/day for the first 2 weeks to assess tolerance
• Injection site: Can be co-administered at a separate site from tesamorelin, or given 4 to 6 hours apart at the same abdominal site
• Timing: Morning injection is most commonly reported, creating a morning/evening split with tesamorelin
• Peptide quality: Source from a 503A or 503B FDA-registered compounding pharmacy; request certificate of analysis (COA) confirming >98% purity by HPLC

Cycle Structure

| Phase | Duration | Tesamorelin | GHK-Cu | |---|---|---|---| | Ramp | Weeks 1 to 2 | 2 mg/day | 1 mg/day | | Maintenance | Weeks 3 to 16 | 2 mg/day | 2 to 3 mg/day | | Taper off | Weeks 17 to 20 | 1 mg/day | 1 mg/day | | Rest | Weeks 21 to 28 | Off | Off |

The rest phase lets pituitary GHRH receptor sensitivity recover. Continuous tesamorelin use beyond 26 weeks without reassessment is not supported by the FDA label [1].

Evidence Quality: What We Know and What We Don't

Honest evidence grading matters for any peptide stack. This combination sits at a specific point on the evidence ladder.

What Is Supported by RCT Data

Tesamorelin's visceral fat reduction is documented in multiple Phase 3 RCTs and two long-term extension studies totaling over 1,000 patient-years of exposure [3][14]. The FDA approved it on this basis. GHK-Cu's wound-healing and skin-remodeling effects are supported by several small RCTs and controlled animal studies [6][11]. These are separate bodies of evidence; no RCT has tested the combination.

What Is Supported Only by Mechanistic Reasoning

The claim that tesamorelin-elevated IGF-1 potentiates GHK-Cu fibroblast signaling is mechanistically plausible based on the known biology of each agent [8][9] but has not been confirmed in a controlled experiment. Claims about additive cognitive benefit, enhanced wound healing compared with either agent alone, or synergistic anti-aging effects fall into this category.

Evidence Gaps to Communicate to Patients

Practitioners should tell patients explicitly:

1. No pharmacokinetic interaction study exists for this pair.
2. The optimal GHK-Cu dose for subcutaneous systemic use is unknown.
3. Long-term safety data for concurrent GH-axis stimulation and copper supplementation have not been published.

A 2022 review in Biomolecules covering GHK-Cu research concluded that "well-designed randomized controlled trials are needed to confirm the therapeutic potential of GHK-Cu in human subjects" [15].

Safety, Monitoring, and Contraindications

Tesamorelin Safety Profile

The most common adverse events in the Phase 3 trials were injection-site reactions (10.3% tesamorelin vs. 4.8% placebo), peripheral edema (6.0% vs. 2.0%), and arthralgia (5.5% vs. 3.0%) [3]. Glucose metabolism requires monitoring: tesamorelin increased fasting glucose by a mean of 3.8 mg/dL in the LIPO trials. Patients with pre-existing diabetes showed greater glycemic variability [3]. The FDA label carries a warning for glucose intolerance, and the drug is contraindicated in patients with active malignancy, hypersensitivity to tesamorelin or mannitol, pituitary tumor or disruption, and pregnancy [1].

GHK-Cu Safety Profile

No serious adverse events have been published for subcutaneous GHK-Cu in human use at doses under 10 mg/day. Copper toxicity from exogenous copper supplementation typically requires chronic ingestion exceeding 10 mg/day of elemental copper according to the NIH Office of Dietary Supplements [16]. At 1 to 3 mg/day of GHK-Cu, the copper content is a small fraction of this threshold. Still, patients with Wilson's disease or other copper metabolism disorders should not use GHK-Cu [16].

Recommended Monitoring Schedule

| Test | Baseline | Week 6 | Week 12 | Week 24 | |---|---|---|---|---| | IGF-1 (serum) | Yes | No | Yes | Yes | | Fasting glucose / HbA1c | Yes | Yes | Yes | Yes | | Serum copper / ceruloplasmin | Yes | No | Yes | Yes | | CBC with differential | Yes | No | Yes | No | | Visceral fat assessment (DEXA or CT) | Yes | No | No | Yes | | Liver function panel | Yes | No | Yes | Yes |

Target IGF-1 levels should remain within the age- and sex-adjusted reference range provided by the assaying laboratory. The Endocrine Society's 2011 growth hormone deficiency guidelines recommend keeping IGF-1 at or below the upper limit of normal for the patient's age [17]. Supraphysiologic IGF-1 raises theoretical oncologic concern, though no causal link to cancer has been established for tesamorelin at the approved dose [1].

Who Is This Stack Appropriate For?

Candidate Profile

This stack may be appropriate for adults who meet all of the following:

• HIV-positive with confirmed lipodystrophy (for on-label tesamorelin use), OR enrolled in a physician-supervised off-label program with documented medical rationale
• Age 25 or older (pituitary axis maturity)
• Fasting glucose <100 mg/dL or well-controlled diabetes with HbA1c <7.5%
• No personal or first-degree family history of pituitary tumors or acromegaly
• Normal serum copper and ceruloplasmin at baseline

Who Should Not Use This Stack

Exclude patients with active malignancy of any type. The FDA label states tesamorelin is contraindicated in oncology patients because GH/IGF-1 signaling may promote tumor cell proliferation [1]. Pregnant women should not use either agent; GHK-Cu's reproductive safety data in humans are absent, and tesamorelin is FDA Pregnancy Category X [1]. Patients with Wilson's disease cannot safely receive exogenous copper in any form [16].

Injection Technique and Practical Considerations

Subcutaneous Injection Protocol

Both peptides are administered subcutaneously. Use a 29 to 31 gauge, 0.5-inch insulin syringe. Pinch a 1-inch fold of abdominal skin, insert the needle at a 45-degree angle, and inject slowly over 5 to 10 seconds. Release the skin fold before withdrawing the needle. Rotate the injection site at least 1 cm from any site used in the prior 48 hours.

Storage and Stability

Tesamorelin (Egrifta SV) reconstituted solution is stable for 24 hours at 2 to 8°C and must not be frozen [1]. GHK-Cu peptide in bacteriostatic water is typically stable for 28 to 30 days refrigerated per compounding pharmacy guidelines, though formal published stability data are limited. Discard any solution that appears cloudy or has visible particles.

Minimizing Injection-Site Reactions

The most common local reactions with tesamorelin are erythema, pruritus, and induration [3]. Allowing the reconstituted solution to reach room temperature (15 to 20 minutes out of refrigerator) before injection reduces stinging. GHK-Cu is generally well tolerated locally; transient flushing at the injection site is occasionally reported in practitioner notes but has not been quantified in any published study.

Drug Interactions and Concomitant Medications

Tesamorelin may reduce the clearance of cytochrome P450 (CYP) substrates that are GH-regulated. The FDA label specifically calls out that GH stimulation can alter the metabolism of cortisol and alter the dose requirements of glucocorticoids in patients on replacement therapy [1]. Patients on ritonavir-boosted HIV regimens showed comparable tesamorelin pharmacokinetics to non-ritonavir users in the LIPO trials, so most antiretroviral regimens do not appear to significantly interfere [3]. GHK-Cu has no published CYP interaction data. Avoid combining tesamorelin with other GH-secretagogues (sermorelin, ipamorelin, CJC-1295) unless under direct endocrinologist supervision, as stacked GH-axis stimulation risks supraphysiologic IGF-1 elevation [17].

Frequently Asked Questions